Congratulations @DrChoueiri for being elected to the @ASCO Board of Directors!! Huge achievement- so well deserved!
Latest posts 5
@dmukherji again brings the patient voice on stage to discuss data on CTLA4 plus PDL1 volrustomic and TIDE-A axitinib discontinuation trial. #ESMO2023 @kcCURE @RCCadvocate
How to optimize GU trials. Come to S100b for a fascinating session wit @BenMironMD @RCCadvocate #ASCO2023 Libby Wulff-Burchfield
Our 5 year data on SABR for #kidneycancer proof efficacy especially for single fraction. Unprecedented data superior to any other ablation technique. Should be considered SOP in RCC not suitable for surgery. Thanks for the amazing team effort!
bit.ly/3UYLQ1Y
bit.ly/3UYLQ1Y
